肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2015年
4期
256-259
,共4页
杭达明%黄灿红%万志龙%蔡晶
杭達明%黃燦紅%萬誌龍%蔡晶
항체명%황찬홍%만지룡%채정
替吉奥%放射疗法,调强适形%食管肿瘤
替吉奧%放射療法,調彊適形%食管腫瘤
체길오%방사요법,조강괄형%식관종류
S-1%Radiotherapy,intensity-modulated%Esophageal neoplasms
目的 探讨替吉奥同期放射治疗局部晚期老年人食管癌的临床疗效和不良反应.方法 选择2011年1月至2013年4月收治的50例局部晚期老年食管癌患者,按信封法随机分为替吉奥同期放疗组(治疗组)25例和单纯放疗组(对照组)25例.两组均采用调强放疗,常规分割,处方剂量均为58～60 Gy,分29～30次给予.治疗组在放疗开始时口服替吉奥胶囊(每天80 mg/m2,2次/d),连服14 d,21d为1个周期,直至放疗结束.结果 47例患者可评价疗效.治疗组完全缓解(CR)5例,部分缓解(PR) 14例,稳定(SD)3例,进展(PD)1例,有效率(RR)为82.6％(19/23);对照组CR 3例,PR12例,SD 6例,PD 3例,RR为62.5 ％(15/24);两组RR差异有统计学意义(P＜0.05).治疗组和对照组1年局部控制率分别为63.6％和43.5％,1年生存率分别为68.2％和39.1％,两组差异均有统计学意义(均P＜0.05).不良反应主要为骨髓抑制、胃肠道反应、放射性食管炎、放射性肺炎等,两组不良反应发生率差异均无统计学意义(均P＞0.05).治疗组骨髓抑制和胃肠道反应发生率稍高于对照组,症状轻微且能耐受,经对症处理后均能完成治疗.结论 替吉奥同期放射治疗局部晚期老年人食管癌近期疗效较好,不良反应可以耐受,值得进一步研究.
目的 探討替吉奧同期放射治療跼部晚期老年人食管癌的臨床療效和不良反應.方法 選擇2011年1月至2013年4月收治的50例跼部晚期老年食管癌患者,按信封法隨機分為替吉奧同期放療組(治療組)25例和單純放療組(對照組)25例.兩組均採用調彊放療,常規分割,處方劑量均為58～60 Gy,分29～30次給予.治療組在放療開始時口服替吉奧膠囊(每天80 mg/m2,2次/d),連服14 d,21d為1箇週期,直至放療結束.結果 47例患者可評價療效.治療組完全緩解(CR)5例,部分緩解(PR) 14例,穩定(SD)3例,進展(PD)1例,有效率(RR)為82.6％(19/23);對照組CR 3例,PR12例,SD 6例,PD 3例,RR為62.5 ％(15/24);兩組RR差異有統計學意義(P＜0.05).治療組和對照組1年跼部控製率分彆為63.6％和43.5％,1年生存率分彆為68.2％和39.1％,兩組差異均有統計學意義(均P＜0.05).不良反應主要為骨髓抑製、胃腸道反應、放射性食管炎、放射性肺炎等,兩組不良反應髮生率差異均無統計學意義(均P＞0.05).治療組骨髓抑製和胃腸道反應髮生率稍高于對照組,癥狀輕微且能耐受,經對癥處理後均能完成治療.結論 替吉奧同期放射治療跼部晚期老年人食管癌近期療效較好,不良反應可以耐受,值得進一步研究.
목적 탐토체길오동기방사치료국부만기노년인식관암적림상료효화불량반응.방법 선택2011년1월지2013년4월수치적50례국부만기노년식관암환자,안신봉법수궤분위체길오동기방료조(치료조)25례화단순방료조(대조조)25례.량조균채용조강방료,상규분할,처방제량균위58～60 Gy,분29～30차급여.치료조재방료개시시구복체길오효낭(매천80 mg/m2,2차/d),련복14 d,21d위1개주기,직지방료결속.결과 47례환자가평개료효.치료조완전완해(CR)5례,부분완해(PR) 14례,은정(SD)3례,진전(PD)1례,유효솔(RR)위82.6％(19/23);대조조CR 3례,PR12례,SD 6례,PD 3례,RR위62.5 ％(15/24);량조RR차이유통계학의의(P＜0.05).치료조화대조조1년국부공제솔분별위63.6％화43.5％,1년생존솔분별위68.2％화39.1％,량조차이균유통계학의의(균P＜0.05).불량반응주요위골수억제、위장도반응、방사성식관염、방사성폐염등,량조불량반응발생솔차이균무통계학의의(균P＞0.05).치료조골수억제화위장도반응발생솔초고우대조조,증상경미차능내수,경대증처리후균능완성치료.결론 체길오동기방사치료국부만기노년인식관암근기료효교호,불량반응가이내수,치득진일보연구.
Objective To evaluate the clinical effects and adverse reactions of concurrent radiotherapy combined with S-1 for elderly patients with locally advanced esophageal cancer.Methods From January 2011 to April 2013,a total number of 50 elderly patients with locally advanced esophageal carcinoma were randomly divided into concurrent chemo-radiotherapy combined with S-1 group (treatment group) (25 cases) and radiotherapy alone group (control group) (25 cases).Intensity modulated radiation therapy (IMRT) was administered in all cases,with a total dose of (58-60) Gy/(29-30) fx,conventional fractionation.Patients in the treatment group received S-1 of 80 mg/m2 orally bid on day 1-14,with 21 days as a cycle.All the patients should take it until the end of the radiotherapy treatment.Results The efficacy of the 47 cases could be evaluated.In treatment group,5 cases achieved CR,14 cases PR,3 cases SD,1 case PD.The response rate (RR) was 82.6 ％ (19/23).In control group,3 cases achieved CR,12 cases PR,6 cases SD,3 cases PD.The RR was 62.5 ％ (15/24).There was a statistical significant difference between the two groups.The one-year local control rates of treatment group and control group were 63.6 ％ and 43.5 ％,respectively,and the one-year overall survival rates were 68.2 ％ and 39.1％,respectively.The main toxicities included bone-marrow suppression,gastrointestinal reactions,radiation esophagitis and radiation pneumonitis.The incidences of bone-marrow suppression and gastrointestinal reactions were higher in treatment group than those in control group,but the toxic reaction was mild and tolerable.There were no significant differences in terms of bone-marrow suppression,gastrointestinal reactions,radiation esophagitis and radiation pneumonitis between both groups.Conclusion Concurrent chemotherapy combined with S-1 is more effective in the treatment of the elderly patients with locally advanced esophageal cancer and the toxicity is tolerable,which is worth studying furtherly.
